The Worldwide Generic Drugs Industry is Projected to Reach $507.8 Billion by 2026 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Generic Drugs - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Amid the COVID-19 crisis, the global market for Generic Drugs estimated at US$365.9 Billion in the year 2020, is projected to reach a revised size of US$507.8 Billion by 2026, growing at a CAGR of 5.6% over the analysis period.

Small-Molecule Generics, one of the segments analyzed in the report, is projected to grow at a 5.2% CAGR to reach US$325.7 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Biosimilars segment is readjusted to a revised 6.3% CAGR for the next 7-year period. This segment currently accounts for a 37.7% share of the global Generic Drugs market.

The U.S. Market is Estimated at $116.2 Billion in 2021, While China is Forecast to Reach $91.2 Billion by 2026

The Generic Drugs market in the U.S. is estimated at US$116.2 Billion in the year 2021. The country currently accounts for a 30.46% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$91.2 Billion in the year 2026 trailing a CAGR of 7.2% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.8% and 5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR while Rest of European market (as defined in the study) will reach US$97.6 Billion by the close of the analysis period.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• Apotex Inc.
• ASKA Pharmaceutical Co., Ltd.
• Aspen Pharmacare Holdings Limited
• AstraZeneca Plc
• Baxter International Inc.
• Dr. Reddy's Laboratories Limited
• Eli Lilly and Company
• Endo International plc
• Fresenius Kabi
• GlaxoSmithKline Plc.
• H. Lundbeck A/S
• Hospira
• Lupin Pharmaceuticals, Inc.
• Mylan N.V.
• Novartis International AG
• Novo Nordisk A/S
• F. Hoffmann-La Roche AG
• Sandoz International GmbH
• Sanofi-Aventis U.S. LLC
• STADA Arzneimittel AG
• Sun Pharma
• Teva Pharmaceutical Industries Ltd.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Generic Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
• Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
• Impact of Covid-19 and a Looming Global Recession
• The Race Between the Virus & Vaccines Intensifies. Amidst this Chaotic Battle, Where is the World Economy Headed in 2021?
• How Fast the World is Vaccinated Will Determine How Soon the Pandemic Will End: Global Number of Annual COVID-19 Vaccine Doses (In Million) for Years 2020 through 2025 by Geographic Region/Country
• Progress on Vaccinations, Why Should Businesses Care?
• These are Times When Questions Abound & Answers Are Few
• With IMF's Upward Revision of Global GDP Forecasts for 2021, Most Companies Are Bullish About a Global Economic Comeback.
• A Strong 2021 Economic Rebound Based On Pent-Up Demand Comes as a Relief for Suffering Industries & Markets: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
• How the Healthcare Industry Has & Continues to be Impacted by the Pandemic & What's the New Normal?
• With the COVID-19 Pandemic Exposing Global Healthcare Unpreparedness, There is Increasing Policy Led Focus on Rebooting Health Systems Worldwide: Current & Required Healthcare Spending as % of GDP

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

• Patent Expiries Set to Widen the Addressable Market for Generic Drugs
• Patent Expiry of Select Major Drugs in the US: 2020-2022
• Robust Demand for Pharmaceutical Drugs Drives Demand for Generic Drugs
• Cost Containment Measures Put Focus on Generics
• Small Molecule Generics Represent the Dominant Segment
• Increasing Demand for Biosimilars, Driven by Patent Expiry of Major Biopharmaceutical Drugs
• Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe
• Progressive Regulatory Framework Accelerates Product Approvals & Subsequently Market Revenues
• Specific Guidelines for Biosimilars in Various Countries with Year of Publication
• Biosimilars Regulatory Agencies in Select Regional Markets
• Biosimilar Approvals in the US (as of February 2021)
• Biosimilar Approvals in Europe (as of January 2021)
• Rising Healthcare Costs Drive Demand for Generic Drugs
• World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
• Aging Population to Propel the Demand for Generic Drugs
• Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
• Rising Prevalence of Chronic Diseases Drive the Demand for Generic Drugs
• Global Cost of Chronic Diseases (In US$ Billion) for the Years 2018 and 2030
• Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/c5psrd

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900